EichorEICHOR
Condition: High Grade Glioma Hgg Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: High Grade Glioma Hgg

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) G
Phase 1/Phase 2 · 127 location(s) · National Cancer Institute (NCI) · NCT05099003Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
Phase 1/Phase 2 · 1 location(s) · Dushu Lake Hospital Affiliated to Soochow University · NCT06018363A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · 70 location(s) · Fore Biotherapeutics · NCT05503797CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children a
Phase 1 · 1 location(s) · OX2 Therapeutics · NCT06305910A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Rec
Phase 1 · 3 location(s) · Neuregen Therapeutics Co., Ltd. · NCT07710690Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurre
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT0754499218F-Fluciclovine PET-MRI in High-grade Glioma
EARLY_Phase 1 · 1 location(s) · Children's Hospital of Philadelphia · NCT05553041Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
EARLY_Phase 1 · 1 location(s) · Eben Rosenthal · NCT07210632Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Phase 2 · 13 location(s) · Nationwide Children's Hospital · NCT05096481Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Phase 2 · 6 location(s) · St. Jude Children's Research Hospital · NCT06528691Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT05843253A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So
Phase 1 · 83 location(s) · Pfizer · NCT05538130A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participant
EARLY_Phase 1 · 2 location(s) · St. Joseph's Hospital and Medical Center, Phoenix · NCT06072586Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard
Phase 1 · 1 location(s) · Sunnybrook Health Sciences Centre · NCT07179328A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patie
NA · 1 location(s) · Daniel Morgenstern · NCT06519682
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.